Biomind Gets Approval in Brazil for Phase 2 DMT Depression Trial

By Matt Grossman

Biomind Labs Inc. said it has received approval from Brazilian authorities for a Phase 2 trial studying the treatment of depression with N, N-dimethyltryptamine, also known as DMT.

The drug is a psychedelic compound that the body produces naturally, and is the principal psychedelic in ayahuasca, a concoction used as a spiritual medicine among some indigenous people in South America, Biomind said.

The Phase 2 study will include 40 patients and will focus on administering the drug to people whose depression has resisted other treatment methods, the company said.

DMT's psychedelic experience typically lasts less than 30 minutes, Biomind said, making it a more practical treatment option than other psychedelics whose effects last much longer.

Write to Matt Grossman at [e-mail]

(END) Dow Jones Newswires

08-18-21 0754ET